Deals of ~$1.4 billion in one week for Life Sciences Team
· Microbiotica/Genentech microbiome collaboration worth up to $534 million
· Hookipa/Gilead deal for immunotherapies against HIV and Hepatitis B potentially in excess of $400 million
· F-star Gamma could receive up to $471 million through acquisition by Denali Therapeutics to deliver biologic therapeutics across the blood-brain barrier
The life sciences team is pleased to have supported three clients that are pioneering disruptive technologies to develop tomorrow’s therapeutics in their announcements around big bio-dollar deals worth some $1.4 billion.
Three deals have been closed in the last week: on 6 June, Microbiotica announced its strategic microbiome collaboration with Genentech in a deal worth up to $534 million in upfront and milestone payments; the day before on 5 June, Hookipa announced its deal with Gilead, a collaboration and license agreement to develop immunotherapies against HIV and Hepatitis B with a potential deal value worth in excess of $400 million, including upfront and milestone payments, plus research and development funding; and last week on 31 May F-star announced the early exercise by Denali Therapeutics of its option to acquire F-star Gamma, for an upfront payment of $24 million with contingent additional milestones up to $447 million.
“All three deals announced in the last week demonstrate how the potential of cutting-edge science being pioneered in Europe with the potential to deliver new therapeutic modalities is being recognised by world-class biopharma companies” said Sue Charles, Instinctif Partners’ Managing Partner and global head of Life Sciences. “It’s an honour to work with F-star, Hookipa and Microbiotica, and to support and celebrate their successes.”